AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
The research, led by Dr. Daniel Myran, a Canada Research Chair in Social Accountability at the University of Ottawa, followed ...
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie (ABBV) said that its Phase 2 trial ...
doidam10 - stock.adobe.com People who land in the ER for psychedelic use are at significantly higher risk of schizophrenia, according to an eye-opening new study. Canadian researchers tracked more ...